The Skin‑ny
The honest lowdown on luxury skincare.
Morning. Pour something hot — you've missed a lot. Brussels just quietly rewrote what's allowed in your skincare, Estée Lauder is showing yet more brands the door, and ectoin (the word about to be on every jar you own) finally gets explained by someone with no skin in the game. Five honest minutes, zero sponsors. Let's go.
In this issue
- 01The Openwhy a Brussels rule reaches your shelf first
- 02The Briefthree things that moved this week
- 03The Signalectoin, rated by formula not story
- 04The Counterlaunches you should know about
- 05One Good Thingthe one we'd actually keep buying
- 06Noteshow we work
Three things that moved this week.
1. The EU just benched twelve ingredients.
The EU has shown twelve cosmetic ingredients the red card over safety concerns. Brands have until 2027 to fall in line, and until mid‑2028 to clear the non‑compliant stuff off shelves for good.
Why it mattersHere's the thing: big brands hate making a different formula for each country, so one Brussels ruling quietly rewrites labels everywhere — your shelf included — long before anyone here demands it. So when a favourite mysteriously gets "improved" this autumn? Now you know. We'll name names as the new formulas land.
2. Estée Lauder's clear‑out continues.
Estée Lauder is reportedly fielding final offers for Too Faced, Smashbox and Dr. Jart+ — about $3bn of brands it spent the last decade collecting, now up for grabs. Out with the old, in with the new: it just scooped up India's Forest Essentials.
Why it mattersThe playbook never changes: discounts first, then a hush‑hush reformulation once the new owner moves in. So if you love something from these lines, grab the version you know now — and give any "new and improved" sticker a solid year of side‑eye.
3. Sunscreen science is sprinting, because regulators shrank the toolbox.
Funny how it works: crack down on sunscreen filters in the EU and US, and suddenly the whole category leaps forward. That was the word from suppliers at this year's big industry fair.
Why it mattersTranslation: the next few years of SPF will be driven by the rulebook, not the marketing team — actual new formulas, for once. We'll tell you which are the real deal and which are just a prettier bottle.
Ectoin, rated by formula not story.
You'll see this word everywhere this year, so let's get you ahead of the curve. Ectoin is a soothing, hydrating ingredient that's been doing its job quietly in German pharmacy skincare for about twenty years — no fanfare, no hype. So why now? Skincare has swung from "strip it back with actives" to "be nice to your barrier," and ectoin is the ideal poster child. Cue its sudden cameo on every jar, from the chemist to the prestige counter.
What the people qualified to judge it sayThe research (much of it funded by the brands selling it — file that away) actually backs it: better hydration, calmer redness, and skin that copes with stronger stuff more happily. The independent experts we trust say it earns its place. Nobody serious is calling it a miracle, mind.
Bottom lineA well‑deserved moment for a properly good calming ingredient. Buy it for calmer, sturdier skin — and roll your eyes at the "longevity" spin, which is pure wishful thinking. Past about £40, you're paying for the jar and the name, not extra ectoin. Which is fine, as long as you're doing it on purpose.
Launches you should know about.
Lancôme has taken the buzzy ingredient behind a cult longevity supplement and folded it into a face cream. Smart, very on‑trend. But the data on the cream itself is still thin, so read it as a glimpse of where the pricey end is heading, not proof it delivers. (Linked — not affiliated.)
Blue Lagoon's spa brand has spun its mineral‑and‑algae complex into a cleansing balm, complete with collagen claims. Gorgeous formulas, this lot. But selling "results" from something you rinse off in ninety seconds? Oldest trick in the book. Buy it as a lovely cleanser and ignore the collagen talk. (Linked — not affiliated.)
Tatcha keeps quietly winning, and the fancy buzzwords it helped make famous are now trickling into cheaper launches about eighteen months on. Right on schedule, as ever.
Azelaic acid, 10%.
While everyone chases this year's shiny new thing, the unglamorous hero dermatologists have backed for decades is just… sitting there. Azelaic acid quietly handles redness, uneven tone and the odd breakout, it's gentle enough for most sensitive skin, and it starts around £9 / $12. Not trendy. Not exciting. Works every single time. This is the one we'd actually keep buying.
As ever: anything that won't settle down belongs with a GP or dermatologist, not an email.
How we work. No paid write‑ups, ever. Sponsors never see our copy before you do, and they get zero say in what we cover. Affiliate links are always labelled right where you'd click — today there are none. Spot a mistake, or just fancy a chat? Hit reply. We read every single one.
Enjoying this? Forward it to the friend who spends rent money on serums.
The Skin‑ny
An independent skincare briefing. Forwarded this? It's free.
Subscribe for freeSent every Thursday
Made on a desk, with too much coffee.